Positive Long-Term Efficacy and Safety of Teriflunomide

 

Annualized relapse rates (ARR) were significantly lowered for patients treated with 14 mg teriflunomide (Aubagio; Sanofi, Bridgewater, NJ) compared with those treated with placebo. The adjusted ARR was .38 for those treated with teriflunomide vs .59 for those given placebo; ARR reduction was similar for men and women. 

Over a cumulative treatment exposure of 1,648 patient years, people treated with teriflunomide were 35% less likely to have a relapse each year (ARR risk reduction [RR] .35; P < .0001). The intention-to-treat group was comprised of 1,708 people, 812 of whom were treated with teriflunomide and 896 who were treated with placebo. Serious adverse events (AEs) occurred in 11.8% of patients given teriflunomide and 12.5% of those who took placebo. 

These data represent pooled analysis from phase 2 and phase 3 clinical trials (NCT01487096, NCT00134563, NCT00803049, NCT00751881, NCT00622700, and NCT00883337) and were presented at the American Conference on Treatment and Research in MMS (ACTRIMS) conference in Dallas, TX February 28-March 1.

 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.

 
  • BRYN MAWR COMMUNICATIONS III, LLC